Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel

KOERS GALAPAGOS 2015

16.480 Posts
Pagina: «« 1 ... 346 347 348 349 350 ... 824 »» | Laatste | Omlaag ↓
  1. Bonzai1 14 mei 2015 16:43
    @Roan: verstandige aanpak, gast. Ik vind dat je soms even moedig moet zijn om je winst te durven nemen - met de gedachte, indien mogelijk - later terug mee te spelen. Blijven zitten vraagt ballen, maar soms eruit stappen ook (vergelijk het met 'kunnen passen bij het pokeren')
  2. [verwijderd] 14 mei 2015 16:45
    Galapagos NV (GLPG) IPO Opens up 10%

    May 14, 2015 10:39 AM
    Today's IPO for Galapagos NV (Nasdaq: GLPG) opened for trading at $46.30 after pricing 6,550,000 new ordinary shares, consisting of 4,996,522 American Depositary Shares at $42.05 per ADS, and 1,533,478 ordinary shares at a price of €37.00 per share, both before underwriting discounts.

    In addition, Galapagos has granted the underwriters an option to purchase up to an additional 749,478 new ordinary shares in the form of ADSs and an option to purchase up to an additional 233,021 new ordinary shares, representing 15% of the ordinary shares and ADSs placed in the global offering. This option can be exercised during the 30 day period commencing 14 May2015.

    Morgan Stanley, Credit Suisse and Cowen and Company are acting as joint book-running managers, and Nomura and Bryan, Garnier & Co. are acting as co-managers, for the global offering. Morgan Stanley is acting as stabilization agent on behalf of the underwriters.

    Galapagos (Euronext: GLPG; OTC: GLPYY) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action, with a pipeline comprising three Phase 2 programs, two Phase 1 trials, five pre-clinical studies, and 20 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. In the field of inflammation, AbbVie and Galapagos signed a collaboration agreement for the development and commercialization of filgotinib. Filgotinib is an orally-available, selective inhibitor of JAK1 for the treatment of rheumatoid arthritis and potentially other inflammatory diseases, currently in Phase 2B studies in RA and in Phase 2 in Crohn's disease. Galapagos reported good activity and a favorable safety profile at 12 weeks in both the DARWIN 1 and 2 trials in RA. AbbVie and Galapagos also signed a collaboration agreement in cystic fibrosis to develop and commercialize molecules that address mutations in the CFTR gene. Potentiator GLPG1837 is currently in a Phase 1 trial, and corrector GLPG2222 is at the pre-clinical candidate stage. GLPG1205, a first-in-class inhibitor of GPR84 and fully-owned by Galapagos, is currently being tested in a Phase 2 proof-of-concept trial in ulcerative colitis patients. GLPG1690, a fully proprietary, first-in-class inhibitor of autotaxin, has shown favorable safety in a Phase 1 trial and is expected to enter Phase 2 in idiopathic pulmonary fibrosis. The Galapagos Group, including fee-for-service subsidiary Fidelta, has approximately 400 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia.

    Categories
    IPOs
    Next Articles
    Galapagos NV (GLPG) Prices 5M ADS, 1.5M Ordinary Share IPO
    May 14, 2015 9:26 AM
    Bryan, Garnier & Co Announces the Successful $275m IPO for Galapagos NV, the Largest Nasdaq IPO of European Biotech
    May 14, 2015 6:57 AM
    Galapagos (Nasdaq: GLPG) to Ring The Nasdaq Stock Market Opening Bell
    May 14, 2015 6:00 AM
    Galapagos raises $275 million gross proceeds with NASDAQ IPO
    May 13, 2015 11:23 PM
  3. [verwijderd] 14 mei 2015 16:47
    quote:

    E.v.B schreef op 14 mei 2015 16:42:

    Ik word hier toch nerveus van zeg
    Beleggen is vooruit kijken,niet naar een eerste dag van een nieuwe ipo.Hahahaha,sluit je ogen en open ze eind 2015 dan spring je 3 maal in de rondte
  4. me_n 14 mei 2015 16:49
    quote:

    adje5 schreef op 14 mei 2015 16:47:

    [...]

    Beleggen is vooruit kijken,niet naar een eerste dag van een nieuwe ipo.Hahahaha,sluit je ogen en open ze eind 2015 dan spring je 3 maal in de rondte
    Haha denk 2 maal ;)
    Maar wijze gedachte, alleen erg moeilijk ( merk het zelf ook)
  5. mr.Franz 14 mei 2015 16:50
    ik ben benieuwd of we nog wijzigingen in het AFM register gaan zien de komende dagen. de volumes zijn er wel naar.
  6. Spreidstand 14 mei 2015 16:53
    quote:

    Edwin S schreef op 14 mei 2015 16:52:

    Ik ben ingestapt op € 41,20 vandaag. Gaan we daar weer boven komen vandaag?
    ja nu al....
16.480 Posts
Pagina: «« 1 ... 346 347 348 349 350 ... 824 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.018
AB InBev 2 5.501
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.671
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 265
Accsys Technologies 23 10.691
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 189
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.752
Aedifica 3 916
Aegon 3.258 322.851
AFC Ajax 538 7.088
Affimed NV 2 6.297
ageas 5.844 109.893
Agfa-Gevaert 14 2.050
Ahold 3.538 74.337
Air France - KLM 1.025 35.045
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.041
Alfen 16 24.857
Allfunds Group 4 1.473
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 406
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.822
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.233
AMG 971 133.359
AMS 3 73
Amsterdam Commodities 305 6.690
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 15.007
Apollo Alternative Assets 1 17
Apple 5 382
Arcadis 252 8.776
Arcelor Mittal 2.033 320.714
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.302
Aroundtown SA 1 219
Arrowhead Research 5 9.739
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.108
ASML 1.766 107.420
ASR Nederland 21 4.486
ATAI Life Sciences 1 7
Atenor Group 1 491
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.673
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.392

Macro & Bedrijfsagenda

  1. 25 februari

    1. Ackermans & Van Haaren Q4-cijfers
    2. Economische groei vierde kwartaal def (Dld)
    3. Home Depot Q4-cijfers (VS)
    4. Case Shiller huizenprijzen december (VS)
    5. Consumentenvertrouwen CB maart (VS)
    6. ASMI Q4-cijfers volitaliteit verwacht
    7. AMC Entertainment Q4-cijfers (VS)
  2. 26 februari

    1. JDE Peet's Q4-cijfers
    2. Wolters Kluwer Q4-cijfers
    3. AB InBev Q4-cijfers
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht